Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry - Wikidata - awgldk - TriplyDB

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry

http://www.wikidata.org/entity/Q35169273

about

Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.Personalized oncology through integrative high-throughput sequencing: a pilot study.The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.Practicing pathology in the era of big data and personalized medicine Prospective enterprise-level molecular genotyping of a cohort of cancer patients.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Racial diversity of actionable mutations in non-small cell lung cancer.Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.Mutation profiling in gallbladder cancer in Indian population Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Existing and emerging technologies for tumor genomic profiling Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity.The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities.Integrating new therapies in the treatment of advanced melanoma.Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective.The State of the Art in Colorectal Cancer Molecular Biomarker Testing.Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.Circulating tumour-derived DNA in metastatic soft tissue sarcoma.Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.Harnessing massively parallel DNA sequencing for the personalization of cancer management.Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.Identifying Actionable Targets in Cancer Patients

P2860

Q26823978-4C87CE8B-400B-4D01-87E9-3778018F9102 Q27851843-0791B15B-5923-49E3-BD65-B631F90B7C19 Q27852360-D05B751C-38C3-4825-9E76-F5ADC632E7BD Q30239901-0020A2F8-F62A-403D-97C9-C08197305CE5 Q30514084-DC0D56F2-5A01-409C-90A9-6EEBE84ADA89 Q30573750-1F8AC1C7-E783-4AEB-BECD-3A975D46800B Q34033475-293F3073-64E5-43BD-93F0-40542A3F504F Q34237470-56B9DFDF-D10F-44F8-93A2-D6CCB962BD76 Q34316552-67A9CF17-1B6B-4234-B776-52DEB4C11610 Q34388847-9A8A9CB0-E113-401E-AC74-C7C4B47F15B8 Q34409739-7877C878-09AF-4EC3-8501-9F79FB9D1F30 Q34781699-4B34D3CF-BBAF-471E-900C-AD8EC4C42A64 Q35007995-FC2D63B8-1DA9-4346-9F6A-9E539B1837D0 Q35670595-30379B3B-E6B9-4DF9-AA18-DCC05AE6B758 Q35756096-3248E183-7A47-48FE-80D5-C9DD759EAD73 Q35758472-00048EE4-E23A-4A65-908F-30A2DE94AC9A Q36896131-75CD2326-36A0-471E-8A90-CBA1FE26BEE7 Q37113976-F5151A67-8B9C-4595-BA2B-789813B76B90 Q37255147-4B350F48-AD87-4D1B-8082-12350A6A6124 Q37352562-E5DB7A34-8E8B-4BFE-9AD6-C02622719080 Q37595248-1983564C-3B66-48D7-921C-0960992224CE Q38012417-096FB27B-3C52-4E9F-8901-3B42A5A41B81 Q38022444-A8F5A5CE-3A1B-45F4-ADAD-2CBDF68BD92B Q38123671-89AEF42A-3101-4EC7-B2A9-D84050BCA5F6 Q38202398-03B3DEA7-F5BB-49B6-B205-B0B681848954 Q38591866-F87B1F9D-0C29-498B-B86B-627FA8E2BD40 Q38724312-D38B1779-6DC2-4552-B006-141E8E94D99B Q42947925-68B66533-C5B1-4D86-BE18-99C6485162CB Q48267582-74E72492-A755-4846-A2E4-9DBE193C8A87 Q52356767-A5CDDD62-7620-4879-8944-B83358C2F77F Q53272132-964A3AAA-343D-4D13-BED2-5E34234AA479 Q54257595-453734BD-4CB9-4746-A36B-4BCBE18B3091 Q54399355-A7E8BF03-92B3-4F12-BB01-C17A07F202FC Q54522930-2C61BBD4-1BE1-40DF-BF10-021902519581 Q57272446-ADFC2422-434E-4857-A80C-D89F2F0767F7

P2860

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry

http://www.wikidata.org/entity/Q35169273

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Multiplex mutation screening b ...... lized cancer medicine registry

@ast

Multiplex mutation screening b ...... lized cancer medicine registry

@en

type

label

Multiplex mutation screening b ...... lized cancer medicine registry

@ast

Multiplex mutation screening b ...... lized cancer medicine registry

@en

prefLabel

Multiplex mutation screening b ...... lized cancer medicine registry

@ast

Multiplex mutation screening b ...... lized cancer medicine registry

@en

P1433

Q35169273-56B148B9-A3F5-4097-8ADC-B25A9349EEAA

P1476

Q35169273-E255421B-3AF5-4263-85DE-94310B858556

P2093

Q35169273-0112D8F4-7143-44CC-B720-DCD5736E7BF3

Q35169273-03F36DE4-A1BC-4EFA-9DD7-061A2633F251

Q35169273-22D9A4C7-C81E-45CE-9993-9B28190084FD

Q35169273-4A4AA0D5-9493-45E4-AC68-CC5E38272482

Q35169273-59734965-04CC-466A-878B-EEF0A210ADE6

Q35169273-5C85C009-7AD3-48CB-8C2B-221E9FE361ED

Q35169273-82BA86F4-78EA-428D-8496-84A9F9467666

Q35169273-9E1D63CA-DA2E-415C-A261-0007D83B5886

Q35169273-9E279FB2-B93E-4E7B-BE0F-FE44F89A6649

Q35169273-A4D5927A-AD68-4BEB-89D4-1B899F7EBD46

P2860

Q35169273-03670CC3-15D2-4D70-9DAB-B078B10C28C5

Q35169273-03A7F7DA-34A5-4A9A-993A-E4D037F59104

Q35169273-03CFE066-89C5-46F3-8BC4-EF9F1A1272ED

Q35169273-051A25C8-3090-438D-A5B8-C55A68A9B152

Q35169273-091C3043-E940-466D-8415-0EF626F9626F

Q35169273-0DC7B906-DAD1-44EE-BF65-B42CFB1C2A0E

Q35169273-0F5C3A53-D6A7-4988-A3F5-17EC1194BBFA

Q35169273-103395CD-BE4E-4D11-B224-B1647E61F0C4

Q35169273-132314EB-77FD-44A5-AC72-BA29F14B0B49

Q35169273-1959CE11-7941-4A5E-A517-76FA1A293BA3

P304

Q35169273-404FF267-F220-4B98-AA39-C34A9DD691D6

P31

Q35169273-2A9A1220-EFD7-4210-9F61-CB99A04EE3AB

P356

Q35169273-D4EF506D-754F-4E69-AA3B-1C86DFDD0EE8

P433

Q35169273-A756A5DB-65B5-4D2D-B0C0-D27B588AB363

P478

Q35169273-C77A2149-C74A-4306-A9AA-94D3E65C29ED

P50

Q35169273-99D957C0-B20F-46B6-9083-B52063F7FFBF

Q35169273-9E63CCDA-7017-461A-A43B-295A6BC92C1D

Q35169273-CFB245B6-EDD7-4740-9502-FA4DCDCB13C2

P577

Q35169273-C42B2FCF-8F8A-4AA5-80F9-B91B96A71EAD

P5875

Q35169273-A3128D3A-EA85-48FE-8A07-3291E3468C6F

P698

Q35169273-2AD5549A-B708-461B-906F-9335EEBB4578

P932

Q35169273-1EB87517-3174-4934-84F6-07BD0016A9DB

P356

J.JMOLDX.2011.04.003

P1433

The Journal of Molecular Diagnostics

P1476

Multiplex mutation screening b ...... lized cancer medicine registry

@en

P2093

Ajia Presnell

http://www.w3.org/2001/XMLSchema#string

Amy Harlow

http://www.w3.org/2001/XMLSchema#string

Andrea Warrick

http://www.w3.org/2001/XMLSchema#string

Arin McKinley

http://www.w3.org/2001/XMLSchema#string

Carol Beadling

http://www.w3.org/2001/XMLSchema#string

Christie Dewey

http://www.w3.org/2001/XMLSchema#string

Christopher L Corless

http://www.w3.org/2001/XMLSchema#string

Dylan Nelson

http://www.w3.org/2001/XMLSchema#string

Emily Justusson

http://www.w3.org/2001/XMLSchema#string

Erin M Forbes

http://www.w3.org/2001/XMLSchema#string

P2860

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Profiling critical cancer gene mutations in clinical tumor samples

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cetuximab for the treatment of colorectal cancer.

Major response to imatinib mesylate in KIT-mutated melanoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

504-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JMOLDX.2011.04.003

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Brian J. Druker

Michael C. Heinrich

Janice Patterson

P577

2011-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51464866

http://www.w3.org/2001/XMLSchema#string

P698

21726664

http://www.w3.org/2001/XMLSchema#string

P932

3157616

http://www.w3.org/2001/XMLSchema#string